(2008)
A research group led by Namnyak has found that although there is a lot of media coverage of Stockholm syndrome, there has not been a lot of research into the phenomenon. What little research has been done is often contradictory and does not always agree on what Stockholm syndrome is. The term has grown beyond kidnappings to all definitions of abuse. It stated that there is no clear definition of symptoms to diagnose the syndrome. FBI law enforcement bulletin (1999)
A 1998 report by the FBI containing over 1,200 hostage incidents found that only 8% of kidnapping victims showed signs of Stockholm syndrome. When victims who showed negative and positive feelings toward the law enforcement personnel are excluded, the percentage decreases to 5%. A survey of 600 police agencies in 1989, performed by the FBI and the University of Vermont, found not a single case when emotional involvement between the victim and the kidnapper interfered with or jeopardized an assault. In short, this database provides empirical support that the Stockholm syndrome remains a rare occurrence. The sensational nature of dramatic cases causes the public to perceive this phenomenon as the rule rather than the exception. The bulletin concludes that, although depicted in fiction and film and often referred to by the news media, the phenomenon actually occurs rarely. Therefore, crisis negotiators should place the Stockholm syndrome in proper perspective.
This new class of antiretrovirals played a critical role in the development of highly active antiretroviral therapy (HAART), which helped significantly lower the risk of death from AIDS-related causes, as seen by a reduction of the annual U.S. HIV-associated death rate, from over 50,000 to about 18,000 over a period of two years.Roche requested and received approval of Invirase via the FDAs "Accelerated Approval" program—a process designed to speed drugs to market for the treatment of serious diseases—a decision that was controversial, as AIDS activists disagreed over the benefits of thorough testing versus early access to new drugs. It was approved again on November 7, 1997, as Fortovase, a soft gel capsule reformulated for improved bioavailability. Roche announced in May 2005 that, given reduced demand, Fortovase would cease being marketed early in 2006, in favor of Invirase boosted with ritonavir, owing to the ability of the latter co-formulated drug to inhibit the enzyme that metabolizes the AIDS drugs. Society and culture
Economics
As of 2015, it is not available as a generic medication. Formulations
Two formulations have been marketed:

a hard-gel capsule formulation of the mesylate, with trade name Invirase, which requires combination with ritonavir to increase the saquinavir bioavailability;
a soft-gel capsule formulation of saquinavir (microemulsion, orally-administered formulation), with trade name Fortovase, which was discontinued worldwide in 2006. References
External links
"Saquinavir". Drug Information Portal. U.S. National Library of Medicine.